Comparative Pharmacology
Head-to-head clinical analysis: EKTERLY versus JYLAMVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EKTERLY versus JYLAMVO.
EKTERLY vs JYLAMVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ekterly is a tissue-selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER) and induces conformational changes leading to ER degradation. It antagonizes ER-mediated gene transcription and signaling, thereby inhibiting ER-dependent breast cancer cell proliferation.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
10 mg orally once daily
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Steady state reached within 2 days. Accumulation negligible with once-daily dosing.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion accounts for 70% of elimination, with 30% hepatobiliary/fecal. Approximately 15% is excreted unchanged in urine; the remainder as glucuronide metabolites.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent